Nrf2 has been demonstrated to be a transcription factor that prevents ROS-induced tissue injury and shows beneficial effects in a variety of kidney diseases, including acute kidney disease (Shelton et al., 2013), chronic kidney disease (Hasegawa et al., 2017), DN (Wu et al., 2016), and hypertension-associated kidney disease (Chang et al., 2013). This evidence concerns the gene NFE2L2 and liver dysplastic nodule.